anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The objective is to evaluate in eutrophic women the impact of intake of moderate amounts of wheat gluten on body weight basal metabolic rate and possible relation to macronutrient intake. For this, 30 volunteers will kept on a restricted diet in gluten-free foods of 6 weeks. At the first moment, a structured Food Frequency Questionnaire will be applied, as well as a 24-hour food register, to evaluate the average food and gluten daily intake. The volunteers will be randomized into two groups, half of them will initiate the experiment by taking 2 placebo muffins daily for 3 weeks (Placebo phase) and the remnant volunteers will take 2 gluten muffins for 3 weeks (Gluten phase). After one day of wash out, the volunteers will be transferred for the other phase to complete 3 more experimental weeks. During these 6 experimental weeks, all volunteers will be instructed to exclude any food containing gluten from their diet. The test food (gluten and placebo muffins) will be produced in the Laboratory of Dietetic Technique of the School of Nursing of the Federal University of Minas Gerais and delivered weekly to each volunteer. Placebo test foods is a corn-based muffin of about 45g. In the Gluten muffins, 10g of corn is replaced by 10g of gluten (corresponding to 7.5g of gluten protein). Each volunteer will be instructed to take 2 (placebo or gluten) muffin/day. To evaluate diet adherence and signs and symptoms of intolerances, volunteers will fill a questionnaire weekly, informing about the consumption of the test food, eventual intake of food containing gluten, and the presence of gastrointestinal signs and symptoms such as constipation, diarrhea, nausea or vomiting etc.
Vulnerable patients with deficits (G8 score \<15 pts) receive a geriatric assessment (Comprehensive geriatric assessment (CGA)) consisting of abbreviated comprehensive geriatric assessment (aCGA), appetite (Mini Nutritional Assessment (short form = MNA-SF)) at the beginning and end of radiotherapy ), physical functionality (Short physical performance battery) and measurement of hand strength. In addition, these patients receive an individualized inpatient geriatric-oncological complex treatment, which is already implemented analogous to the palliative complex treatment. The patients receive targeted support from trained nursing staff, social services, physiotherapy, nutritional advice, hospital pharmacies and psycho-oncology. At the end of the oncological therapy and for the first aftercare after the end of therapy, the questionnaires on quality of life are filled out again in order to analyze changes. Initially, 20 patients are to be treated in a first phase (feasibility) in this concept of geriatric-oncological complex treatment in order to build up and expand the necessary structures for an interdisciplinary complex treatment and to set parameters for adherence to the therapy concept and maintaining quality of life and independence in the activities of the daily life for this collective of patients. As part of a follow-up study, vulnerable patients are then to be stratified and randomized using these parameters so that a more detailed analysis is possible.
PROBLEM TO BE SOLVED: To provide a solubilizor, an emulsifier and a dispersing agent capable of improving concn. of a matter to be solubilized, a matter to be emulsified and a matter to be dispersed in a water-containing solvent by incorporating the polymer of monomer composition containing a hydrophilic monomer having the group expressed y specified formula at side chain as effective component. SOLUTION: In the solubilizer, emulsifier and dispersing agent the polymer obtained by polymerizing the monomer composition containing the hydrophilic monomer having the group expressed by formula I (wherein, each of R<1> , R<2> and R<3> is hydrogen atom or 1-4C alkyl group and may be the same or different with each other) at the side chain is incorporated as effective component. Then in the hydrophilic monomer, the polymer obtained by polymerizing 100-20wt.% 2-(methacryloyloxy)ethyl-2'-(alkyl substd. or unsubstd. ammonio)ethylphosphate expressed by formula II (wherein, each of R<1> , R<2> and R<3> is hydrogen atom or the 1-4C alkyl group and may be the same or different with each other) and a hydrophobic monomer is incorporated as the effective component.
A composition is provided for whitening a tooth in a dental arch, including at least 30 % by weight of potassium hydrogen peroxymonopersulfate sulfate (2KHSO5.KHSO4.K2SO4) in a slurry or in a dry form, wherein the composition does not cause damage visible to the naked eye to a soft tissue during a treatment period. A composition is also provided for whitening a tooth including at least 30 % by weight of potassium hydrogen peroxymonopersulfate (2KHSO5.KHSO4.K2SO4) in a slurry or dry form, wherein the composition does not include a peroxide bleaching agent. In another embodiment, a method is provided for whitening a tooth in a dental arch. The method includes (1) contacting the dental arch with a composition comprising at least 30 % by weight of potassium hydrogen peroxymonopersulfate sulfate (2KHSO5.KHSO4.K2SO4) in a slurry or in an aqueous solution, wherein the pH of said composition is adjusted from about pH=5.0 to about pH=8.5, and wherein the contacting does not cause damage visible to the naked eye to a soft tissue of the dental arch during a treatment period; and (2) removing the composition from the dental arch. In a further embodiment, a method is provided for whitening a tooth including contacting the tooth with a composition including at least 30 % by weight of potassium hydrogen peroxymonopersulfate sulfate (2KHSO5.KHSO4.K2SO4) in a slurry or in an aqueous solution, wherein the pH of the composition is adjusted to range from about 5.0 to about 8.5, and removing the composition comprising at least 30 % by weight of potassium hydrogen peroxymonopersulfate sulfate (2KHSO5.KHSO4.K2SO4). The method also includes contacting the tooth with a composition including a peroxide bleaching agent, wherein the agent generates hydrogen peroxide as 15 % or less by weight of the composition; and removing the composition including a peroxide bleaching agent. A kit is also provided for whitening teeth including a carrier means being compartmentalized to receive in close confinement therein one or more containers including a first container containing potassium hydrogen peroxymonopersulfate sulfate (2KHSO5.KHSO4.K2SO4) and an agent to adjust the pH from about 5.0 to about 8.5.
Type 2 airway inflammation (T2AI), driven by type 2 innate lymphoid and CD4+ T helper 2 cells, leads to various diseases and conditions, such as chronic rhinosinusitis with nasal polyps, allergic rhinitis, and asthma. Emerging evidence suggests the involvement of extracellular vesicles (EVs) in these diseases. In this review, we describe the immunological T2AI pathogenic mechanisms, outline EV characteristics, and highlight their applications in the diagnosis and treatment of T2AI. An extensive literature search was conducted using appropriate strategies to identify relevant articles from various online databases. EVs in various biological samples showed disease-specific characteristics for chronic rhinosinusitis with nasal polyps, allergic rhinitis, and asthma, with some demonstrating therapeutic effects against these conditions. However, most studies have been limited to in vitro and animal models, highlighting the need for further clinical research on the diagnostic and therapeutic applications of EVs.
Drugs that Inhibit CYP3A4 (Ketoconazole)

CYP3A4 is a major metabolic pathway for elimination of eszopiclone. The exposure of eszopiclone was increased by coadministration of ketoconazole, a potent inhibitor of CYP3A4. Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly. Dose reduction of LUNESTA is needed for patient co-administered LUNESTA with potent CYP3A4 inhibitors [see Dosage and Administration (2.3)].

Drugs that Induce CYP3A4 (Rifampicin)

Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. A similar effect would be expected with eszopiclone. Combination use with CYP3A4 inducer may decrease the exposure and effects of LUNESTA.
Lymph node status is one of the most important prognostic factors in colorectal cancer, and accurate pathological nodal staging and detection of lymph node metastases is crucial for determination of post-operative management. Current guidelines, including the TNM staging system and European Society for Medical Oncology (ESMO) guidelines, recommend examination of at least 12 lymph nodes. However, identification of an adequate number of lymph nodes can be challenging, especially in the setting of neoadjuvant treatment, which may reduce nodal size. In this study, we investigated 384 colorectal cancer resections that were processed at our department of pathology between January 2012 and December 2022, in which the number of detected lymph nodes was less than 12 subsequent to conventional preparation of mesocolic fat tissue. By means of acetone compression, lymph node harvest increased significantly (p < 0.0001), and the intended number of ≥ 12 lymph nodes was achieved in 98% of resection specimens. The number of nodal positive cases increased significantly from n = 95 (24.7%) before versus n = 131 (34.1%) after acetone compression due to additionally identified lymph node metastases (p < 0.001). In 36 patients (9.4%) initially considered as nodal negative, acetone compression led to a staging adjustment to a nodal positive category and thereby drove a recommendation to offer post-operative therapy. In conclusion, acetone compression is a reliable and useful method implementable in routine surgical pathology for the retrieval of lymph nodes in colorectal cancer specimen, allowing for an adequate lymph node sampling and an increase in nodal staging reliability.
EEG activity will be recorded using the standard CE marked portable EEG amplifier with four electrodes on the scalp. The test will be controlled using a tablet. The captured waveforms will be sent to the cloud where the NBT Artificial Intelligence (AI) algorithm analyses EEG activity, analyses the data and decides whether the test was or was not completed successfully. The test takes approximately 15 minutes to complete. The device has been trained with EEG data from full term infants. It is not a diagnostic test, simply a screener.

The EEG and anonymised patient data collected during the NBT test will be processed and stored in the NBT secure AWS infrastructure. During the feasibility study, the result (EEG reading or result of AI algorithm) from the device will not be available to the research team so as not to influence clinical practice.
A pharmaceutical composition containing Brassica rapa extracts is provided to prevent and treat kidney toxicity diseases by cisplatin and cardiac circulation disease by LDL oxidation. A pharmaceutical composition for preventing and treating kidney toxicity diseases which is caused by an anticancer drug comprises 0.01-98 weight% of 4-methoxyindole-3-acetonitrile as an active ingredient. The 4-methoxyindole-3-acetonitrile is isolated from a Brassica rapa. An anticancer adjuvant having suppression activity to kidney toxicity comprises the 4-methoxyindole-3-acetonitrile. A pharmaceutical composition for preventing and treating cardiac circulation diseases comprises the 4-methoxyindole-3-acetonitrile as an active ingredient. The cardiac circulation diseases are hyperlipidemia, cerebral artery, coronary heart disease, arteriosclerosis or myocardial infarction.
The invention discloses application of circ-0000423 in preparation or screening of a colon cancer drug. The high expression of circ-0000423 is closely related to the stage, differentiation degree and prognosis of intestinal cancer, and the higher the expression degree is, the later the disease stage is, and the worse the differentiation and prognosis are, which indicates that circ-0000423 is closely related to the malignant behavior of colorectal cancer. The circ-0000423 can adsorb the cancer suppressor gene miR-519 to promote the invasion and metastasis of colorectal cancer by a cerRNA mechanism. The circ-0000423 can be used as a therapeutic target to be applied to the preparation or screening of medicines for treating colon cancer or inhibiting the invasion and migration of colon cancer. The circ-0000423 can be used as a detection target to be applied to the preparation of colorectal cancer diagnostic reagents. The circ-0000423 can be used as a detection target to prepare a reagent for predicting the stage, differentiation degree or prognosis of colorectal cancer.
PURPOSE:To obtain the titled compound useful as an anti-inflammatory agent and a transcutaneous absorbefacient in high purity and yield in a short time, by reacting azacycloheptan-2-one with a dodecyl halide in a non-aqueous system in the presence of a phase-transfer catalyst. CONSTITUTION:1-Dodecylazacycloheptan-2-one can be produced by reacting azacycloheptan-2-one with a dodecyl halide in a non-aqueous system in the presence of a phase-transfer catalyst of formula (X<-> is proper anion; R1-R4 are alkyl, aralkyl or together with bonding N atom form a heterocyclic group) (e.g. tetramethylammonium chloride). The reaction is preferably carried out by using 1-3pts. of an inert solvent (especially preferably toluene) based on 1pt. of the raw material and using a base such as sodium hydroxide as a hydrogen halide acceptor.
Hepatocellular carcinoma (HCC) is one of the common and fatal malignant tumors worldwide, and the burden of HCC is particularly severe in China. Physiologically, the blood supply to healthy liver is mainly from the portal vein, supplemented by the hepatic artery. While in the development of HCC, the main source of blood supply to HCC is changed from the portal vein to the hepatic artery. The characteristics of HCC vascularization are important for imaging, surgery, interventional therapy, targeted therapy, etc. Even in the future, with the development of radiation therapy technology, such as proton and heavy ion therapy and artificial intelligence technology, the dynamic changes in HCC blood perfusion can be used as a new biomarker of tumor activity to provide accurate information on the intensity modulation of radiotherapy, so that accurate measurements of HCC blood perfusion is of great significance in guiding the diagnosis and treatment of HCC. The technologies for measurement of HCC blood perfusion have developed from invasive techniques, such as inert gas scavenging, electromagnetic flowmeter, and radionuclide-labeled erythrocyte elution in the middle of the last century to the present non-invasive techniques of CT. With the development of CT imaging technology in the last 30 years, the CT-based imaging technology can assess the status of organ and tissue perfusion relatively easily and accurately. In this paper, the various CT measurement techniques of blood perfusion in HCC were categorized into three types: semi-quantitative technique, relative quantitative technique, and absolute quantitative technique. Their basic principle, scanning methods, and clinical applications were discussed to provide a reference for the diagnosis and treatment of HCC.
Morphine sulfate extended-release tablets contain morphine, a Schedule II controlled substance. As an opioid, morphine sulfate exposes its users to the risks of addiction, abuse, and misuse. Because extended-release products such as morphine sulfate deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of morphine present [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed morphine sulfate. Addiction can occur at recommended doses and if the drug is misused or abused.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing morphine sulfate, and monitor all patients receiving morphine sulfate for development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as morphine sulfate, but use in such patients necessitates intensive counseling about the risks of proper use of morphine sulfate along with intensive monitoring for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.3)].

Abuse or misuse of morphine sulfate extended-release tablets by crushing, chewing, snorting, or injecting the dissolved product will result in the uncontrolled delivery of morphine and can result in overdose and death [see Overdosage (10)].

Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing morphine sulfate. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [see Patient Counseling Information (17)]. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
This invention discloses a method of administering direct precursors of the hormone dihydrotestosterone as a means of increasing androgen levels in humans. As men age, a decline in androgenic hormone levels is typically noted, possibly resulting in muscle mass, bone density and energy loss. Various methods have therefore been developed to supplement androgens for men with declining levels. This invention teaches using precursors to testosterone, in that DHT and its precursors cannot be converted to estrogens in the human body. This may be a very advantageous trait for aging men at risk for benign prostatic hypertrophy, as estrogenic and androgenic action are both needed to induce this condition. As testosterone is the primary substrate for the synthesis of estradiol in men, its use as a target for androgen replacement may pose a greater health risk.
NEW MATERIAL:A compound of formula I (B is nucleic acid base derivative; R is H, acyl, phosphate group or protective group; n is l-4). EXAMPLE:9-[(lR,2S,3S)-2,3-bis(hydroxymethyl)cyclobutylmethyl]guanine. USE:An antiviral drug, carcinostatic agent. PREPARATION:A reaction is made in the presence of a basic catalyst (e.g. potassium carbonate) in a solvent such as N,N-dimethylformamide between (A) a compound of formula II (X is eliminable group) and (B) a nucleic acid base derivative at 0 deg.C to the solvent reflux temperature followed by, if needed, removing the protective group, thus obtaining the objective compound of the formula I. Said nucleic acid base derivative is e.g. adenine, being used at a level of 0.5-10 equivalent times the compound of the formula I.
Participants with LGMD2E/R4 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
LY2940680 administered orally once daily at escalating doses (92.5 milligrams per square meter \[mg/m\^2\] up to 370 mg/m\^2) for two 28 day cycles. Lower dose levels (23 mg/m\^2 and 46 mg/m\^2) may also be explored, if necessary. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
<P>PROBLEM TO BE SOLVED: To provide a preparation which does not develop transient irritation while having microbial contamination resistance even without using a general- purpose preservative such as parabens.  <P>SOLUTION: This cosmetic for hypersensitive skin is obtained by adding (1) 1,2-hexylene glycol and (2) an antimicrobial phospholipid to cosmetic. Linoleamidopropyl PG-dimonium chloride phosphate, cocoamidopropyl PG- dimonium chloride phosphate and sodium coco PG-dimonium chloride phosphate, or the like, are preferably exemplified as the antimicrobial phospholipid. The cosmetic as a preferable form does not contain the conventional preservative such as methylparaben. A polyhydric alcohol except the 1,2-hexylene glycol may be cited as a preferable arbitrary component.  <P>COPYRIGHT: (C)2004,JPO
OBJECTIVE: Acute myocardial infarction (AMI) poses a serious burden on public health. Shenmai Injection (SMI) has been reported to have a cardioprotective effect and is used clinically attributed to its targeting of ferroptosis. This study aims to explore the underlying mechanisms of SMI in treating AMI through the application of network pharmacology analysis.
METHODS: This study utilized network pharmacology to identify the bioactive ingredients and potential targets of SMI in treating AMI. A rat model of AMI was created by ligating the coronary arteries of rats, and a cell model was established by subjecting H9c2 cells to oxygen-glucose deprivation (OGD) to reveal the cardioprotective effects of SMI. Western blotting was employed to measure protein expressions, while hematoxylin-eosin staining was used to observe relevant pathological changes. Enzyme linked immunosorbent assay was conducted to measure the levels of biomarkers associated with cardiac injury and oxidative stress.
RESULTS: A comprehensive analysis revealed a total of 225 putative targets of SMI in the context of AMI which exerted regulatory effects on numerous pathways and targeted multiple biological processes. AKT1 was identified as a core target mediating the effects of SMI on AMI by topological analysis. In vivo experiments revealed that SMI attenuated myocardial injury, oxidative stress, and ferroptosis in rats with AMI. Furthermore, SMI was found to enhance the expression levels of p-AKT1 and p-mTOR proteins in the myocardial tissues of rats afflicted with AMI. Similar findings were also observed in H9c2 cells subjected to OGD. Of particular interest, the suppression of OGD-induced iron accumulation, oxidative stress, and ferroptosis-associated proteins by SMI in H9c2 cells was reversed upon inhibition of the AKT1/mTOR pathway via MK2206.
CONCLUSION: This study revealed that SMI exerts a protective effect against myocardial injury and ferroptosis caused by AMI via the activation of the AKT1/mTOR pathway.
FIELD: medicine, endocrinology. SUBSTANCE: invention relates to agents used for prophylaxis and treatment of patients with diabetic complications including 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)-benzyl]-3,5-dimethylbenzoic acid, its optically active compound or its pharmaceutically acceptable salt as an active component. Invention relates to also a pharmaceutical composition and method of prophylaxis and treatment of patients with diabetic complications, in part, to diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis. Proposed drug shows the prolonged effect in very low doses being in a single every day administration. EFFECT: enhanced effectiveness of agent. 27 cl, 7 tbl, 5 ex